Advertisement

Journal of Neurology

, Volume 263, Issue 2, pp 257–262 | Cite as

Frequency of MELAS main mutation in a phenotype-targeted young ischemic stroke patient population

  • Turgut TatlisumakEmail author
  • Jukka Putaala
  • Markus Innilä
  • Christian Enzinger
  • Tiina M. Metso
  • Sami Curtze
  • Bettina von Sarnowski
  • Alexandre Amaral-Silva
  • Gerhard Jan Jungehulsing
  • Christian Tanislav
  • Vincent Thijs
  • Arndt Rolfs
  • Bo Norrving
  • Franz Fazekas
  • Anu Suomalainen
  • Edwin H. Kolodny
Original Communication

Abstract

Mitochondrial diseases, predominantly mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), may occasionally underlie or coincide with ischemic stroke (IS) in young and middle-aged individuals. We searched for undiagnosed patients with MELAS in a target subpopulation of unselected young IS patients enrolled in the Stroke in Young Fabry Patients study (sifap1). Among the 3291 IS patients aged 18–55 years recruited to the sifap1 study at 47 centers across 14 European countries, we identified potential MELAS patients with the following phenotypic features: (a) diagnosed cardiomyopathy or (b) presence of two of the three following findings: migraine, short stature (≤165 cm for males; ≤155 cm for females), and diabetes. Identified patients’ blood samples underwent analysis of the common MELAS mutation, m.3243A>G in the MTTL1 gene of mitochondrial DNA. Clinical and cerebral MRI features of the mutation carriers were reviewed. We analyzed blood samples of 238 patients (177 with cardiomyopathy) leading to identification of four previously unrecognized MELAS main mutation carrier-patients. Their clinical and MRI characteristics were within the expectation for common IS patients except for severe hearing loss in one patient and hyperintensity of the pulvinar thalami on T1-weighted MRI in another one. Genetic testing for the m.3243A>G MELAS mutation in young patients with IS based on phenotypes suggestive of mitochondrial disease identifies previously unrecognized carriers of MELAS main mutation, but does not prove MELAS as the putative cause.

Keywords

Mitochondrion Ischemic stroke Young Diagnosis MELAS Mitochondrial disease Mutation 

Notes

Acknowledgments

During this study, AS was funded by Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, European Research Council, University of Helsinki, and Academy of Finland. We are grateful to all study investigators and the core facility study team at the University of Rostock.

Compliance with ethical standards

Funding

The sifap1 study (http://www.sifap.eu/, NCT00414583) has been supported by an unrestricted scientific Grant from Shire Human Genetic Therapies to the University of Rostock.

Conflicts of interest

None.

Ethical standards

Ethics committee of the Medical Association Mecklenburg-Vorpommern (Board 2), University of Rostock, Rostock, Germany has approved this study on 14-SEPTEMBER-2006.

References

  1. 1.
    Ylikallio E, Suomalainen A (2012) Mechanisms of mitochondrial diseases. Ann Med 44:41–59CrossRefPubMedGoogle Scholar
  2. 2.
    Finsterer J (2006) Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 114:217–238CrossRefPubMedGoogle Scholar
  3. 3.
    Sakuta R, Goto Y, Horai S, Nonaka I (1993) Mitochondrial DNA mutations at nucleotide positions 3243 and 3271 in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a comparative study. J Neurol Sci 115:158–160CrossRefPubMedGoogle Scholar
  4. 4.
    Finsterer J (2009) Management of mitochondrial stroke-like-episodes. Eur J Neurol 16:1178–1184CrossRefPubMedGoogle Scholar
  5. 5.
    Al-Hassnan ZN, Rashed MS, Al-Dirbashi OY, Patay Z, Rahbeeni Z, Abu-Amero KK (2008) Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome with stroke-like imaging presentation: clinical, biochemical and molecular analysis. J Neurol Sci 264:187–194CrossRefPubMedGoogle Scholar
  6. 6.
    Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Tatlisumak T (2009) Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 40:1195–1203CrossRefPubMedGoogle Scholar
  7. 7.
    Salih MA, Abdel-Gader AG, Zahraa JN, Al-Rayess MM, Alorainy IA, Hassan HH, Ruitenbeek W, Zeviani M (2006) Stroke due to mitochondrial disorders in Saudi children. Saudi Med J 27(Suppl 1):S81–S90PubMedGoogle Scholar
  8. 8.
    Yesilot Barlas N, Putaala J, Waje-Andreassen U, Vassilopoulou S, Nardi K, Odier C, Hofgart G, Engelter S, Burow A, Mihalka L, Kloss M, Ferrari J, Lemmens R, Coban O, Haapaniemi E, Maaijwee N, Rutten-Jacobs L, Bersano A, Cereda C, Baron P, Borellini L, Valcarenghi C, Thomassen L, Grau AJ, Palm F, Urbanek C, Tuncay R, Durukan Tolvanen A, van Dijk EJ, de Leeuw FE, Thijs V, Greisenegger S, Vemmos K, Lichy C, Bereczki D, Csiba L, Michel P, Leys D, Spengos K, Naess H, Tatlisumak T, Bahar SZ (2013) Etiology of first-ever ischaemic stroke in European young adults: the 15 cities young stroke study. Eur J Neurol 20:1431–1439PubMedGoogle Scholar
  9. 9.
    Rolfs A, Martus P, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, Bottcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B, sifap1 Investigators (2011) Protocol and methodology of the Stroke in Young Fabry Patients (sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18–55 years. Cerebrovasc Dis 31:253–262CrossRefPubMedGoogle Scholar
  10. 10.
    Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, Bottcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B, Stroke in Young Fabry Patients (sifap) Investigators (2013) Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 44:340–349CrossRefPubMedGoogle Scholar
  11. 11.
    Fazekas F, Enzinger C, Schmidt R, Dichgans M, Gaertner B, Jungehulsing GJ, Hennerici MG, Heuschmann P, Holzhausen M, Kaps M, Kessler C, Martus P, Putaala J, Ropele S, Tanislav C, Tatlisumak T, Norrving B, Rolfs A, sifap1 Investigators (2013) MRI in acute cerebral ischemia of the young: the Stroke in Young Fabry Patients (sifap1) study. Neurology 81:1914–1921CrossRefPubMedGoogle Scholar
  12. 12.
    von Sarnowski B, Putaala J, Grittner U, Gaertner B, Schminke U, Curtze S, Huber R, Tanislav C, Lichy C, Demarin V, Basic-Kes V, Ringelstein EB, Neumann-Haefelin T, Enzinger C, Fazekas F, Rothwell PM, Dichgans M, Jungehulsing GJ, Heuschmann PU, Kaps M, Norrving B, Rolfs A, Kessler C, Tatlisumak T, sifap1 Investigators (2013) Lifestyle risk factors for ischemic stroke and transient ischemic attack in young adults in the Stroke in Young Fabry Patients study. Stroke 44:119–125CrossRefGoogle Scholar
  13. 13.
    ‘t Hart LM, Jansen JJ, Lemkes HH, de Knijff P, Maassen JA (1996) Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging. Hum Mutat 7:193–197CrossRefPubMedGoogle Scholar
  14. 14.
    Rahman S, Poulton J, Marchington D, Suomalainen A (2001) Decrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet 68:238–240CrossRefPubMedGoogle Scholar
  15. 15.
    Suomalainen A, Majander A, Pihko H, Peltonen L, Syvanen AC (1993) Quantification of tRNA3243(Leu) point mutation of mitochondrial DNA in MELAS patients and its effects on mitochondrial transcription. Hum Mol Genet 2:525–534CrossRefPubMedGoogle Scholar
  16. 16.
    Suomalainen A, Syvanen AC (2003) Analysis of nucleotide sequence variations by solid-phase minisequencing. Methods Mol Biol 226:361–366PubMedGoogle Scholar
  17. 17.
    Malfatti E, Laforet P, Jardel C, Stojkovic T, Behin A, Eymard B, Lombes A, Benmalek A, Becane HM, Berber N, Meune C, Duboc D, Wahbi K (2013) High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutation. Neurology 80:100–105CrossRefPubMedGoogle Scholar
  18. 18.
    Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, Sue CM (2007) Population prevalence of the MELAS A3243G mutation. Mitochondrion 7:230–233CrossRefPubMedGoogle Scholar
  19. 19.
    Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF (2008) Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 83:254–260CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R (2013) The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation—implications for diagnosis and management. J Neurol Neurosurg Psychiatry 84:936–938CrossRefPubMedGoogle Scholar
  21. 21.
    Tschampa HJ, Urbach H, Greschus S, Kunz WS, Kornblum C (2013) Neuroimaging characteristics in mitochondrial encephalopathies associated with the m.3243A>G MTTL1 mutation. J Neurol 260:1071–1080CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Turgut Tatlisumak
    • 1
    • 2
    • 3
    Email author
  • Jukka Putaala
    • 3
  • Markus Innilä
    • 4
  • Christian Enzinger
    • 5
  • Tiina M. Metso
    • 3
  • Sami Curtze
    • 3
  • Bettina von Sarnowski
    • 6
  • Alexandre Amaral-Silva
    • 7
    • 8
  • Gerhard Jan Jungehulsing
    • 9
  • Christian Tanislav
    • 10
  • Vincent Thijs
    • 11
  • Arndt Rolfs
    • 12
  • Bo Norrving
    • 13
  • Franz Fazekas
    • 5
  • Anu Suomalainen
    • 3
    • 4
  • Edwin H. Kolodny
    • 14
  1. 1.Institute of Neuroscience and PhysiologySahlgrenska Academy, University of GothenburgGothenburgSweden
  2. 2.Department of NeurologySahlgrenska University HospitalGothenburgSweden
  3. 3.Department of NeurologyHelsinki University Central HospitalHelsinkiFinland
  4. 4.Research Program for Molecular NeurologyUniversity of HelsinkiHelsinkiFinland
  5. 5.Department of NeurologyMedical University of GrazGrazAustria
  6. 6.Department of NeurologyErnst-Moritz-Arndt University MedicineGreifswaldGermany
  7. 7.Department of NeurologyUnidade Cerebrovascular Hospital de São JoséLisbonPortugal
  8. 8.Department of NeurologyHospital Vila Franca de XiraVila Franca de XiraPortugal
  9. 9.Department of NeurologyCharite UniversityBerlinGermany
  10. 10.Department of NeurologyUniversity of GiessenGiessenGermany
  11. 11.Austin Health and Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneHeidelbergAustralia
  12. 12.Albrecht-Kossel-Institute for NeuroregenerationUniversity of RostockRostockGermany
  13. 13.Department of Clinical Neurosciences NeurologyLund UniversityLundSweden
  14. 14.Department of NeurologyNew York University School of MedicineNew YorkUSA

Personalised recommendations